YOKNEAM, ISRAEL--(Marketwire - Jan 24, 2012) - Syneron Medical Ltd. (NASDAQ: [ ELOS ]), the leading global aesthetic device company, announced today that China's State Food and Drug Administration (SFDA) has cleared its eLaser, eLight, eMatrix, eMax and VelaShape systems, significantly expanding the Company's product offering to Chinese aesthetic practitioners and patients.

Louis P. Scafuri, Chief Executive Officer of Syneron Medical, said, "The recent SFDA approval of these five products is a significant milestone for Syneron's business in China. We can now offer our Chinese customers some of the Company's bestselling aesthetic devices, including the eMatrix with its category creating Sublative Rejuvenation treatment for the face and VelaShape, the market leading body contouring system. We look forward to launching these products and are working diligently to gain approvals for additional aesthetic device products."

Dr. Shimon Eckhouse, Co-founder and Chairman of the Board of Directors of Syneron Medical and co-inventor of Syneron's proprietary elos technology, commented, "Syneron is at the leading edge of the innovation curve for aesthetic treatments, both in terms of technology and customer-centric product offerings. We also are the first company to establish a Medical Advisory Board focused solely on Asian countries, demonstrating our commitment to this important patient population. Our elos technology provides proven safe and efficacious treatments for Asian skin tone and texture, making our products ideal for the Chinese market, and we are thrilled with these recent SFDA clearances."

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: [ ELOS ]) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.